Impact of coxsackievirus-B4E2 combined with a single low dose of streptozotocin on pancreas of outbred mice: investigation of viral load, pathology and inflammation

Mehdi A. Benkahla1, Famara Sane3, Antoine Bertin1, Anais-Camille Vreulx1, Firas Elmastour1, Hela Jaidane2,3, Rachel Desailloud4 & Didier Hober1

Coxsackieviruses B (CV-B) belong to the EV-B species. CV-B and particularly CV-B4 are thought to be involved in the development of chronic diseases like type 1 diabetes (T1D). The mechanisms of the enteroviral pathogenesis of T1D are not well known, yet. The in vitro studies are rich with information but in vivo infection models are needed to investigate the impact of viruses onto organs. Our objective was to study the impact of CV-B4E2 combined with a single sub-diabetogenic dose of streptozotocin (STZ) on the pancreas of mice. The infection with CV-B4E2 of CD1 outbred mice treated with a sub-diabetogenic dose of STZ induced hyperglycemia and hypoinsulinemia. Along with the chemokine IP-10, viral RNA and infectious particles were detected in the pancreas. The pancreas of these animals was also marked with insulitis and other histological alterations. The model combining STZ and CV-B4E2 opens the door to new perspectives to better understand the interactions between virus and host, and the role of environmental factors capable, like STZ, to predispose the host to the diabetogenic effects of enteroviruses.

Coxsackievirus B (CVB) 1 to 6, are viruses with RNA genome that belong to the species Enterovirus B (EV-B), of the Enterovirus genus of the Picornaviridae family. CVB causes asymptomatic infections in humans but also various acute diseases like pancreatitis, myocarditis and aseptic meningitis, as well as chronic diseases such as dilated cardiomyopathy1,2 and type 1 diabetes (T1D)1–4. T1D is a proinflammatory progressive disease characterized by specific islet β cell destruction or dysfunction and loss of insulin secretion. The role of CV-B, especially CV-B4, in the pathogenesis of T1D is strongly suspected1–3.

During CV-B4 infection, the viral RNA is detected by TLR39, which activates the Toll/interleukin-1 receptor domain-containing adaptors inducing IFN (TRIF) that then induces the expression of type I IFNs and the overexpression of IFN-inducible protein 10 (IP-10). TLR3 also activates Nuclear Factor Kappa Beta (NF-κβ) which stimulates the production of pro-inflammatory cytokines such as IL-1β, IL-6 and TNFα7–9. Several studies have reported that lymphocytes infiltrating islets overexpress IP-10 and that β cells under the influence of cytokines (TNFα, IFNγ) produce IP-10. Furthermore, IP-10 has been identified as the most dominant chemokine expressed in the islet’s environment of prediabetic animals and T1D patients10–14.

Type 1 diabetes can be induced in animals by various means15–17. Diabetes can be induced by streptozotocin (STZ), a glucosamine-nitrosourea compound that specifically targets pancreatic β cells. It was isolated for the first time from the Streptomyces achromogenes bacteria. The molecular structure is a 2-deoxy-D-glucose molecule substituted by an N-methyl-N-nitrosourea group at the carbon C2 level18. The selective toxicity towards pancreatic...
β cells is related to the glucose fraction in its chemical structure, which allows the STZ to enter the cell via the low affinity glucose transporter-2 (GLUT2). The β cells are also more sensitive to STZ because they are more active than other cells to incorporate glucose. Insulin-producing cells that do not express GLUT2 are resistant to STZ toxicity. Once inside, it is rapidly metabolized and specifically affects the DNA and the mitochondria. In mitochondria, STZ acts by inhibiting the production of ATP and by affecting NAD (Nicotinamide Adenine Dinucleotide) at the same time. Furthermore, STZ binds to DNA to form dimers (DNA adducts), activating the DNA repair process that uses a poly (ADP-ribose) polymerase converting NAD to ADP-ribose. Since the production of NAD is disrupted, the enzyme cannot perform its function, which leads to the death of insulin secretory cells by apoptosis or necrosis, which contributes to the development of diabetes. The administration of multiple low doses of STZ in animals induces initial cell damage by alkylating the DNA in islet cells and/or by spontaneously releasing NO. Then, mononuclear cells infiltrate the islets which triggers a process that results in islet destruction and diabetes. It was reported that chemokines, like IP-10, are critical determinants of multiple low doses of STZ-induced diabetes.

It was reported that inbred mice treated with a single sub-diabetogenic dose of streptozotocin developed diabetes when they were infected with EMC virus, CV-B3 or CV-B4. The CD1 mouse strain is derived from a Swiss stock and is of great interest for toxicology and virology since its genetic structure is close to that of natural Mus musculus populations. CD1 mice are susceptible to diabetogenic viruses such as EMCV and CV-B4. The purpose of the present study was to investigate the impact of CV-B4E2 combined with a single sub-diabetogenic dose of streptozotocin on the pancreas and on pancreatic β cells of outbred mice.

**Results**

**Diabetes induced by CV-B4E2 in mice treated with a sub-diabetogenic dose of streptozotocin.**

Streptozotocin solubilized in sodium citrate buffer (pH 4.5) was injected intraperitoneally at various concentrations to 3 week old male CD1 mice. It was determined that the sub-diabetogenic dose of STZ not causing hyperglycemia was 35 mg/kg while the diabetogenic dose was 45 mg/kg and more (Supplementary Fig. S1). Mice pretreated with 35 mg of STZ/kg or sodium citrate buffer were inoculated 12 days later with CV-B4E2 (2.10^4 TCID₅₀) or culture medium (Fig. 1).

Blood glucose levels in control mice injected with culture medium, CV-B4E2, or a sub-diabetogenic dose of STZ were lower than 300 mg/dl (300 mg/dl is the threshold for hyperglycemia) whereas they were higher in animals treated with STZ combined with CV-B4E2. Blood glucose values ranging from 423 to 600 mg/dl and above (600 mg/dl was the upper limit of detection of the test) were measured day 6 through day 21 after virus inoculation in out of 5 mice. The blood glucose levels day 6 through day 21 were higher than those of controls (p < 0.05). In one event, one mouse had a blood glucose level of 300 mg/dl 12 days post-inoculation (Fig. 1A–D).

Twenty days after inoculation, the mice were sacrificed and the pancreas and blood were recovered. The detection of infectious particles by end-point dilution assay in pancreatic tissue homogenates was negative (data not shown). In contrast, there was enteroviral RNA in the pancreas of CV-B4E2-infected mice regardless of whether it was treated with STZ: 2.33 +/- 0.36 and 1.63 +/- 0.59log copies/ng of total RNA respectively (p > 0.05) (Fig. 1E).

Twelve days after being treated with sub-diabetogenic dose of STZ (35 mg/kg), the three week old male CD1 mice were infected with CV-B4E2 (2.10^4 TCID₅₀). The mice were sacrificed on day 5, 10, 15, 20, and 25 post-infection to recover the pancreas and blood; their blood glucose levels were also measured on the days they were sacrificed.

The blood that was obtained by cardiac puncture from euthanised mice was centrifuged and the serum recovered to measure the level of insulin by ELISA.

The blood glucose levels in mice inoculated with culture medium or with CV-B4E2 ranged between 112 and 164 mg/dl and the serum insulin levels were 2.30 to 5.14µg/l (Fig. 2A,B). In STZ-treated mice, the blood glucose levels at day 15, day 20 and day 25 were slightly higher (up to 279 mg/dl) and the blood insulin levels ranged between 0.53 and 2.66µg/l (Fig. 2C). In mice inoculated with STZ and then infected with CV-B4E2 12 days later (Fig. 2D) the levels of blood glucose were higher compared with the values obtained in controls (p < 0.05) (Fig. 2A–C). In mice inoculated with STZ and CV-B4E2 the levels of insulin were lower than those of animals inoculated with medium or CV-B4E2 (p < 0.05), and to a lesser extent than those of animals inoculated with STZ (p > 0.05) (Fig. 2A–D).

Infectious particles were found on day 5 in the pancreas of mice infected with CV-B4E2 regardless of whether they were treated with STZ. On day 10, day 15, day 20 and day 25, the detection of infectious particles in the pancreas of both groups of mice was negative (Fig. 2E).

Enteroviral RNA was found in the pancreas recovered from mice inoculated with CV-B4E2 on day 5 and 10 post-infection and from mice inoculated with STZ/CV-B4E2 on day 5, 10 and 15 post-infection. In pancreas harvested after 15 days post-infection, viral RNA was undetectable in mice infected with CV-B4E2 regardless of whether they were treated with STZ (Fig. 2F).

**Impact of CV-B4E2 on the pancreas of mice treated with a sub-diabetogenic dose of streptozotocin.**

In mice inoculated with a sub-diabetogenic dose of STZ and CV-B4E2, hyperglycemia and hypoinsulinemia were observed on day 5 post-infection. Therefore it was decided to use this model to study viral load and inflammatory cytokines in pancreas collected on day 5 post-infection and to analyze the impact of the virus through a histological analysis of the pancreas.

In mice treated with STZ and then infected with CV-B4E2, the levels of blood glucose were higher and the levels of blood insulin were lower compared with controls on day 5 post inoculation or mock-infected. 4 out of 5 mice had a blood glucose level above 300 mg/dl (see Fig. 3A). In mice treated with STZ, the levels of blood
glucose were increased as well but at a lesser extent (224 +/− 57.37 mg/dl). Infectious particles were found in the pancreas of CV-B4E2-infected mice regardless of whether they were treated with STZ (3.41 +/− 0.53 vs 2.58 +/− 0.60 log TCID50/mg p > 0.05). Enteroviral RNA was found in the pancreas of CV-B4E2-infected mice and STZ/CV-B4E2-infected mice (2.77 +/− 0.44 vs 3.34 +/− 0.30 log copies/ng of total RNA, p < 0.05 (Fig. 3D).

In CV-B4E2-infected mice treated with STZ, the mean levels of TNFα and IFNγ in pancreatic tissues were not higher than those obtained in pancreas of mice inoculated with buffer and medium (mock) (see Fig. 3E,F) whereas the mean levels of IP-10 were higher (Fig. 3G) (19.7 +/− 8.9 vs 7.8 +/− 6.2 pg/ng of total RNA p < 0.05). It was noted that the level of IP-10 was low (7.70 pg/ng of total RNA) in the animal with blood glucose lower than 300 mg/dl (see the dark inverted triangle symbol in Fig. 3G).

When mice treated with STZ were inoculated with UV-inactivated CV-B4E2, the blood glucose levels were not higher than those of controls (ranging values: 112 to 168 mg/dl) (data not shown).

The histological analysis of the pancreas of 5 out of 6 CV-B4E2-infected mice treated with STZ, with blood glucose levels >300 mg/dl, displayed an inflammatory infiltrate of exocrine tissue and around Langerhans islets, an adipose involution and abnormal morphology of endocrine tissue. In contrast, there was no lesion of pancreas
obtained from the CV-B4E2-infected mice treated with STZ, of which the blood glucose level was <300 mg/dl and from control mice that were inoculated with buffer and culture medium, STZ or CV-B4E2 (Fig. 4).

**Discussion**

This study is different in many aspects from those of other investigators who reported that inbred mice exposed to a sub-diabetogenic dose of STZ followed by inoculation of an enterovirus (CV-B3 or CV-B5) or a cardiovirus (EMC) developed hyperglycemia. In the present study, the diabetogenic effect of CV-B4E2 inoculated in outbred CD1 mice treated with STZ was observed, and the relationship between hyperglycemia and hypoinsulinemia as well as the presence of viruses and inflammatory markers in the pancreas was investigated.

Several considerations in the present report are noteworthy. Blood glucose level higher than 300 mg/dl was obtained in mice receiving a single non-diabetogenic dose of STZ (35 mg/kg) by the intraperitoneal route prior to the inoculation of CV-B4E2 by the same route (2.10⁶ TCID₅₀) 12 days later. In contrast, when mice received either the same dose of STZ or the same viral inoculum, the blood glucose levels remained below 300 mg/dl. The blood
glucose values observed in non-fasting CD1 mice in our experiments (100–150 mg/dl) were close to those measured in non-fasting SJL mice (80–120 mg/dl) by other investigators\(^2^7\). The infection can only be confirmed by the presence of virus in tissues. The infection of mice in our study was evidenced by the presence of infectious viral particles...
particles and by the quantification of viral RNA in pancreas. Infectious viral particles were found in the organ 5 days after inoculation of CV-B4E2 but not later than that. Nevertheless, viral RNA was detected up to 15 days post-inoculation but not on day 20 and beyond in most animals. In mice sacrificed on day 20 and day 25, enteroviral RNA was not found suggesting that the virus had been cleared. In some STZ-treated mice inoculated with CV-B4E2, normal blood glucose and insulin levels indicated that the virus had no impact on glucose homeostasis – possibly because of a low inoculum. In contrast, it was observed that in a STZ-treated mouse infected with the virus, enteroviral RNA was present in the pancreas on day 21. Nevertheless, blood glucose and insulin levels were normal, suggesting that the diabetogenic effect of CV-B4E2 in animals exposed to STZ depended on host factors. Whatever these factors, clearly the effect of the virus in mice treated with STZ depended on the occurrence of an infection since animals receiving STZ followed by inactivated CV-B4E2 did not develop hyperglycemia.

The role of inflammation in the development of type 1 diabetes is strongly suspected28. In mice treated with STZ prior to the infection with CV-B4E2, the inflammation of pancreas was studied. Disparities concerning glucose homeostasis as well as the presence of virus in pancreas were observed 5 days after the inoculation of CV-B4E2; therefore, the inflammatory profile was investigated in the organ collected on that date. The pancreas

Figure 4. Pancreatic lesions in mice treated with streptozotocin and inoculated with CV-B4E2. CD1 mice were treated with STZ (35 mg/kg) and then 12 days later were inoculated with CV-B4E2 (2.10^4 TCID_{50}). Controls were treated with buffer or STZ then inoculated with culture medium or with CV-B4E2. The animals were sacrificed at day 5 post inoculation. The pancreas was collected in buffered formalin and then processed as described in the Materials and Methods section. The pictures show a representative aspect of lesions of pancreas from mice treated with STZ prior to inoculation with CV-B4E2: inflammatory infiltrate (A), fat involution (B,C) and abnormal morphology of endocrine tissue (D,E). They also show a representative aspect of pancreas from controls treated with buffer (F) or STZ (G) then inoculated with culture medium (F,G) and a representative aspect of pancreas from controls treated with CV-B4E2 (H).
was prepared in presence of protease inhibitors and inflammatory cytokines (IP-10, TNFα and IFNγ). The concentrations were determined using enzyme immunoassays, as described previously, to study the inflammatory profile of various tissues in animals exposed to LPS. In the present study, the results were standardized with respect to the total amount of RNA contained in the organ fragment instead of the total amount of protein as described by other researchers. Thus it was observed that the pancreatic concentrations of TNFα and IFNγ were not significantly different in control mice and in animals exposed to either STZ or CV-B4E2 or to a combination of both. In contrast, the pancreatic levels of IP-10 in hyperglycemic mice exposed to STZ prior to CV-B4E2 were significantly higher than in controls. Nevertheless, the values were not higher than those obtained in animals which received either STZ or CV-B4E2 and that were not hyperglycemic. Thus, the increase in the concentration of pancreatic IP-10 was not related to the hyperglycemia observed in mice treated with STZ prior to CV-B4E2 inoculation. However, it was observed that IP-10 values were higher in animals with hyperglycemia than in the others without hyperglycemia. All these animals were infected as evidenced by the detection of infectious virus particles and viral RNA in their pancreas. It can be assumed that the infection of pancreatic cells was involved in the impact of CV-B4 infection onto STZ-treated mice. It had already been reported that CVB-4 could replicate and induce CPE in mouse pancreatic β cells in vitro. It was also observed that pancreatic sections from mice inoculated with CV-B4 showed the localization of the viral protein VP1 within insulin+ β cells and within exocrine tissue. Furthermore, it was demonstrated that CVB can replicate in islets of mice when the intraislet environment is suitably altered. It can be hypothesized that a direct effect of CV-B4 on β cells and/or other pancreatic cells resulted in hyperglycemia and pancreatic tissue lesions observed in STZ-treated animals inoculated with the virus. Indeed, the levels of infectious virus and viral RNA were around 4 log TCID50/mg of tissue and 4 log viral RNA copies/ng of total RNA respectively. However, if the proportion of infected β cells was low, an indirect effect through the release of various mediators cannot be excluded. Further studies are needed to determine the relationship between the extent of infection of β cells by the virus and its impact on the pancreas in mice treated with a single subdiabetogenic dose of STZ.

The levels of IP-10, but not those of TNFα and IFNγ, increased in mice exposed to STZ and CV-B4E2; therefore, it can be suggested that the inflammatory response was more likely related to pancreatic cells producing IP-10 rather than immune system cells producing TNFα and IFNγ – otherwise all the cytokine levels would have increased. This pattern of inflammatory reaction was also observed in mice exposed to STZ or CV-B4E2, but under these conditions the animals were not hyperglycemic. Thus, the excessive levels of IP-10 were not correlated with the hyperglycemia induced in mice by the combined effect of STZ and CV-B4E2. Nevertheless, in the pancreas of each hyperglycemic mouse treated with STZ prior to inoculation with CV-B4E2, lesions and inflammatory infiltrates of endocrine tissue were observed, whereas there was no lesion in the pancreas from a normoglycemic mouse exposed to the same treatment as well as from normoglycemic mice exposed to STZ or CV-B4E2. Altogether, these results indicate that in STZ-treated mice, CV-B4E2 can induce alterations in endocrine pancreatic tissue that are associated with disparities of glucose homeostasis observed in these animals. It remains to be determined whether other cytokines than IP-10 and/or other factors induced by CV-B4E2 in mice treated with STZ are involved in hypoinsulinemia associated with hyperglycemia.

Hypoinsulinemia in animals was associated with lesions of pancreatic tissue, which was probably due to direct and indirect effects of the virus, including inflammation of the tissue, especially production of IP-10, and intervention of other factors. Interestingly, it has been reported that STZ in rat β pancreatic cells (cell line INS1) negatively regulated the PI3k/AKT/ERK/mTOR pathway and had a significant impact on β cell survival, normal morphology, cell mass, and reduced intracellular insulin production. This pathway was involved in CV-B-induced autophagy in HeLa cells as well. Whether or not a subdiabetogenic dose of STZ combined with CV-B4E2 has an impact on the PI3k/AKT/ERK/mTOR pathway resulting in a disturbance of glucose homeostasis in vivo is an open question. The mechanisms of hypoinsulinemia in mice treated with STZ and then inoculated with CV-B4E2 remains to be elucidated.

The rapid onset of diabetes induced by STZ, prior to inoculating CV-B4E2, in mice in our experiments is reminiscent of a similar pattern of disturbance of glucose homeostasis observed in humans with fulminant diabetes characterized by the rapid onset of hyperglycemia resulting from a failure/accelerated alteration of pancreatic islet cells. The model combining STZ and CV-B4E2 in CD1 mice opens the door to new perspectives to better understand the mechanisms of fulminant diabetes. Moreover, in the context of the hypothesis of the role of enteroviruses in autoimmune type 1 diabetes, which is more common compared to fulminant diabetes, the model combining STZ and CV-B4E2 on one hand opens perspectives to better understand the interactions between virus and host that participate in the pathogenesis of enterovirus-induced disease, and on the other hand opens perspectives to study the role of environmental factors capable, like STZ, to predispose the host to the diabetogenic effects of enteroviruses. Future studies will be directed along this line in the laboratory.

Material and Methods

Streptozotocin. Streptozotocin (Sigma-Aldrich, St-Louis, MO, USA) was dissolved in sodium citrate buffer (Sigma-Aldrich, pH 4.5) at a concentration of 22.5 mg/mL. A dose of 35 mg/kg was immediately injected intra-peritoneally. The STZ solution must be extemporaneously prepared.

Cell lines. HEp-2 cells (ATCC, Manassas, VA, USA) cultured in MEM medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 50 μg/mL of streptomycin, 50 U/mL of penicillin (BioWhittaker, Walkersville, MD, USA) and 1% non-essential amino acids (Thermo Fisher Scientific) at 37 °C and incubated in a 5% CO2 atmosphere.
**Virus, virus titration and viral inactivation by UV.** CV-B4E2 provided by Ji-Won Yoon (Calgary, Canada) was propagated on HEp-2 cells (ATCC). Three days post inoculation, the flasks are freeze-thawed three times, and centrifuged at 2,000 × g for 10 min at 4 °C. The supernatant was aliquoted and stored at −80 °C.

The virus titers in supernatants of cell cultures or organ homogenates were assessed using the end-point dilution assay and the Spearman-Karber method was used to calculate the tissue culture 50% infectious dose (TCID50)39. For UV inactivation, CV-B4E2 was diluted in MEM medium and subsequently irradiated in six-well cell culture dish for 10 minutes at an intensity of 254 µW/CM2 using a Germicidal UV lamps. Type: VL-4C (Vilber, Germany).

**Mice.** CD1 male mice were obtained from Envigo RMS Sarl (Harlan Laboratories, Gannat, France). All experiments were done in accordance with French and European guidelines for animal care, and were approved by the Ethical committee for animal experimentation of Nord-Pas-de-Calais (France). Mice were given ad libitum access to sterile water and commercial sterile food pellets (SAFE, Augy, France) and were maintained in a 12 h light/dark cycle. All blood glucose measurements were done in the morning, the mouse was placed in a tube restrainer then the tail vein was punctured with a 30G needle and a small droplet of blood was placed into the blood glucose strip inserted in the glucometer (Bayer Healthcare, Loos, France).

CD1 male mice, aged 3 weeks, were inoculated intraperitoneally with a dose of 35 mg STZ/kg. At day 12, following treatment with STZ, these same mice were inoculated with 200 µl of a suspension of CV-B4E2 at 2.10^4 TCID50. At the end of the follow-up, the animals were sacrificed by cervical dislocation, and their pancreas is recovered in buffered formalin for histopathology or frozen at −80 °C for RNA extraction or infectious particles titration.

**RNA extraction.** The pancreas is first weighed and then crushed using a tissue ripper (Qiagen, Hilden, Germany) in 1 ml of PBS, supplemented with a protease inhibitor cocktail (ULTRA Tablets, Mini, EASYpack, Roche, Basel, Switzerland) and then centrifuged at 2,500 × g at 4 °C for 10 min and then aliquoted and stored at −80 °C.

Total RNA was extracted using Tri-Reagent (Sigma-Aldrich), as described elsewhere40. The RNA thus obtained is aliquoted and stored at −80 °C until use. One of the aliquots was directly used for the RNA quantification by Nanodrop spectrophotometer (Thermofisher Scientific).

**Quantitative RT-PCR.** The RNA retrotranscription was performed using the Affinityscript® QPCR cDNA Synthesis kit (Agilent Technologies, Les Ulis, France). Quantitative real-time PCR for cDNA amplification was carried out with the Brilliant® II QPCR kit (Agilent technologies) on the MX3000P® instrument (Agilent technologies). Enterovirus 71 RNA (Vircell, Granada, Spain) was used as standard for quantification. The oligonucleotides and the reaction conditions were described previously41.

**Measurement of IP-10, TNFα, IFN-γ and Insulin protein.** Fragments of pancreas were homogenized in 1 ml of PBS supplemented with a protease inhibitor cocktail (cOmplete ULTRA Tablets, Mini, EASYpack, Roche) after centrifugation at 2,500 × g at 4 °C for 10 min. The supernatant was used to evaluate the levels of IP-10, TNFa and IFNγ. The results were normalized with total RNA harvested from cells.

IP-10, TNFα (Thermofisher Scientific), IFN-γ (Covalab, Villeurbanne, France) were measured by ELISA according to the manufacturer's instructions. The sensitivity of each assay was 7.8 pg/ml, 15 pg/ml, and 15 pg/ml respectively.

Blood was obtained by cardiac puncture from euthanised mice to measure the level of insulin by ELISA according to the manufacturer's instructions, the sensitivity of the assay was 0.2 μg/l (Mercodia, Uppsala, Sweden).

**Histological analysis.** The organs were fixed in buffered formalin, embedded in paraffin, and cut into 5 μm thick sections. The sections are subsequently deparaffinized and then dehydrated with xylene for 10 minutes. The cuts are then rehydrated by decreasing degrees of ethanol (100, 95, 70 and 50°) and finally with double distilled water. Staining is done for 15 min in hematoxylin, followed by washing with running water, a differentiation step which consists of a 1% HCl ethanol bath, and then incubation in water for 5 min. Staining of the cytoplasm is carried in eosin for 5 min followed by washing with water to remove excess dye. The sections are again dehydrated and mounted on superfrrost plus slides for observation using Axiolab (Z1) scanner (Zeiss, Oberkochen, Germany). The histological examinations were blinded.

**Statistical analysis.** The statistical analysis of the results was performed with the student T-test and Welch’s correction test, when appropriate (GraphPad Prism quickCalcs, San Diego, CA, USA). The differences were considered significant for a p value < 0.05.

**References**
1. Hober, D. et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes. Clin. Exp. Immunol. 168, 47–51 (2012).
2. Tapparel, C., Siegrist, F., Petty, T. J. & Kaiser, L. Picornavirus and enterovirus diversity with associated human diseases. Infect. Genet. Evol. 14, 282–293 (2013).
3. Hober, D. & Sauter, P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol 6, 279–289 (2010).
4. Hyöty, H. Viruses in type 1 diabetes. Pediatr Diabetes 17(Suppl 22), 56–64 (2016).
5. Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. *Lancet* **383**, 69–82 (2014).
6. Richer, M. J., Lavallée, D. J., Shainina, I. & Horwitz, M. S. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. *PloS ONE* **4**, e4127 (2009).
7. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. *Cell* **140**, 805–820 (2010).
8. Yokota, S., Okabayashi, T. & Fujii, N. The battle between Virus and Host: Modulation of Toll-Like Receptor Signaling Pathways by Virus Infection. *Mediators Inflammation* **2010**, e184328 (2010).
9. Kawai, T. & Akira, S. TLR signaling. *Cell Death Differ*. **13**, 816–825 (2006).
10. Frigerio, S. et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. *Nat. Med.* **8**, 1414–1420 (2002).
11. Roep, B. O. et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. *Clin. Exp. Immunol.* **159**, 338–343 (2010).
12. Uno, S. et al. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. *Endocr. J.* **57**, 991–996 (2010).
13. Horwitz, E. et al. Cell DNA Damage Response Promotes Islet Inflammation in Type 1 Diabetes. *Diabetes* **67**, 2305–2318 (2018).
14. Martin, A. P. et al. The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. *J. Immunol.* **178**, 4623–4631 (2007).
15. King, A. J. F. The use of animal models in diabetes research. *Br. J. Pharmacol.* **166**, 877–894 (2012).
16. Graham, M. L. & Schuurman, H.-J. Validity of animal models of type 1 diabetes, and strategies to enhance their utility in translational research. *Eur. J. Pharmacol.* **759**, 221–230 (2015).
17. Jaidane, H. et al. Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. *Diabetes Metab. Res. Rev.* **25**, 591–603 (2009).
18. Herr, R. R., Jahne, K. J. & Argoudelis, A. D. The structure of streptozotocin. *J. Am. Chem. Soc.* **89**, 4808–4809 (1967).
19. Elsner, M., Guldabakö, B., Tiedge, M., Munday, R. & Lenzen, S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. *Diabetologia* **43**, 1528–1533 (2000).
20. Okamoto, H. & Takasawa, S. Recent advances in physiological and pathological significance of NAD+ metabolites: roles of poly(ADP-ribose) and cyclic ADP-ribose in insulin secretion and diabetogenesis. *Nutr Res Rev* **16**, 253–266 (2003).
21. Junod, A., Lambert, A. E., Stauffacher, W. & Renold, A. E. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. *J Clin Invest* **48**, 2129–2139 (1969).
22. Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. *Science* **193**, 415–417 (1976).
23. Kwon, N. S., Lee, S. H., Choi, C. S., Kho, T. & Lee, H. S. Nitric oxide generation from streptozotocin. *FASEB J.* **8**, 529–533 (1994).
24. Kolb-Bachofen, V., Epstein, S., Kiesel, U. & Kolb, H. Low-dose streptozotocin-induced diabetes in mice. Electronic microscopy reveals single-cell insulitis before diabetes onset. *Diabetes* **37**, 21–27 (1988).
25. Tomolo, A., Onodera, T., Yoon, J. W. & Notkins, A. L. Induction of diabetes by cumulative environmental insults from viruses and chemicals. *Nature* **288**, 383–385 (1980).
26. Preecchelvaloa, J. et al. Pathophysiology of the pancreas after oral infection of genetically diverse mice with coxsackievirus B4-E2. *Arch. Virol.* **160**, 103–115 (2015).
27. Horwitz, M. S., Illic, A., Fine, C., Rodriguez, E. & Sartovitch, N. Coxsackievirus-mediated hyperglycemia is enhanced by reinfecction and this occurs independent of T cells. *Virology* **314**, 510–520 (2003).
28. Cabrera, S. M., Henschel, A. M. & Hessner, M. J. Innate inflammation in type 1 diabetes. *Transl Res* **167**, 214–227 (2016).
29. McAlpin, E., Obert, L., Chupka, J. & Sigler, R. Detection of cytokine protein expression in mouse lung homogenates using suspension bead array. *J Immunol* **3**, 15 (2006).
30. Frisk, G., Grapengiesser, L. & Diderholm, H. Impaired Ca2+ response to glucose in mouse beta-cells infected with coxsackie B or Echo virus. *Virus Res.* **33**, 229–240 (1994).
31. Edstrom, M. et al. Target cell defense prevents the development of diabetes after viral infection. *Nat. Immunol.* **3**, 373–382 (2002).
32. Drescher, K. M., Kono, K., Bopegamage, S., Carson, S. D. & Tracy, S. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection. *Virology* **329**, 381–394 (2004).
33. Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL10) in autoimmune diabetes. *Autoimmun Rev* **13**, 272–280 (2014).
34. Chang, H. et al. The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells. *Int. J. Mol. Med.* **40**, 182–192 (2017).
35. Yoo, Y.-M. & Park, Y. C. Streptozotocin-Induced Autophagy Reduces Intracellular Insulin in Insulomina INS-1E Cells. *DNA and Cell Biology* **37**, 160–167 (2018).
36. Tanaka, S. et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. *Diabetes* **58**, 2283–2293 (2009).
37. Aida, K. et al. RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. *Diabetes* **60**, 884–889 (2011).
38. Deeds, M. C. et al. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. *Lab. Anim.* **45**, 131–140 (2011).
39. Jaidane et al. Infection of primary cultures of murine splenic and thymic cells with coxsackievirus B4. *Microbiol Immunol.* **42**, 50–56 (2008).
40. Elmasour, F. et al. Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system. *Virulence* **7**, 527–535 (2016).
41. Alidjimou, E. K., Sané, F., Engelmann, I. & Hofer, D. Serum-dependent enhancement of the infection with Coxsackievirus B4-induced production of IFN-α, IL-6 and TNFα by peripheral blood mononuclear cells. *J. Mol. Biol.* **425**, 5020–5031 (2013).
Author Contributions
M.A.B., F.S. and A.C.V. carried out the experiments. M.A.B. and D.H. prepared the figures and analysed the data. M.A.B. and D.H. wrote the manuscript. F.E., A.B. and H.J. participated in carrying out experiment. D.H., H.J. and R.D. designed the project and D.H. supervised the project. All the authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46227-3.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019